Header and Body 2

Problem Addressed

Antibiotic resistant bacteria are an urgent threat to modern medicine. Worldwide there are 30 million new antibiotic-resistant infections diagnosed every year and 5 million of these cases will result in death. Furthermore, the emergence of antibiotic resistant bacteria currently outpaces new drug development, and there is therefore a desperate need to develop new antibiotic therapies. Antimicrobial peptides (AMPs) have been proposed as a promising new antibiotic modality. AMPs are small naturally occurring proteins with potent antimicrobial properties; however, most AMPs either display only limited antimicrobial activity or are highly toxic to human cells. This technology is a panel of new rationally-designed AMPs that display both improved toxicity profiles and improved potency.